57 related articles for article (PubMed ID: 37345121)
1. Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.
Lu HH; Chiu NT; Tsai MH
Ann Nucl Med; 2024 Apr; ():. PubMed ID: 38647876
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan.
Yao SF; Huang WJ; Wei TC; Wang YF; Lin KH; Hu LH; Ting CH; Lee TH; Yeh SH; Peng NJ
J Chin Med Assoc; 2024 May; ():. PubMed ID: 38771079
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
Anido-Herranz U; Fernandez-Calvo O; Ruiz-Bañobre J; Martinez-Breijo S; Fernandez-Nuñez N; Nogareda-Seoane Z; Garrido-Pumar M; Casas-Nebra J; Muñiz-Garcia G; Portela-Pereira P; Gomez-Caamaño A; Perez-Fentes DA; Santome-Couto L; Lázaro M; Molina-Diaz A; Medina-Colmenero A; Vazquez-Estevez S
Front Oncol; 2024; 14():1385466. PubMed ID: 38774416
[TBL] [Abstract][Full Text] [Related]
4. Automated Bone Scan Index as Predictors of Survival in Prostate Cancer.
Wiyanto J; Shintawati R; Darmawan B; Hidayat B; Kartamihardja AHS
World J Nucl Med; 2017; 16(4):266-270. PubMed ID: 29033673
[TBL] [Abstract][Full Text] [Related]
5. Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Blas L; Shiota M; Matsumoto T; Hori Y; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Nov; 30(11):1029-1034. PubMed ID: 37501328
[TBL] [Abstract][Full Text] [Related]
6. NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide.
Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Blas L; Takamatsu D; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
Drug Resist Updat; 2023 Sep; 70():100990. PubMed ID: 37478518
[TBL] [Abstract][Full Text] [Related]
7. Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone-A Retrospective Study.
Chen HX; Tsai LH; Chang CH; Wu HC; Lin CC; Lin CH; Yeh CC; Yang CR; Lien CS; Chang YH; Liang JA; Chen GH; Hsiao PJ; Hsieh PF; Huang CP
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444626
[TBL] [Abstract][Full Text] [Related]
8. Theranostics and artificial intelligence: new frontiers in personalized medicine.
Belge Bilgin G; Bilgin C; Burkett BJ; Orme JJ; Childs DS; Thorpe MP; Halfdanarson TR; Johnson GB; Kendi AT; Sartor O
Theranostics; 2024; 14(6):2367-2378. PubMed ID: 38646652
[TBL] [Abstract][Full Text] [Related]
9. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
[TBL] [Abstract][Full Text] [Related]
10. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
Yanagisawa T; Kawada T; Rajwa P; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; König F; Pallauf M; Pradere B; Karakiewicz PI; Nyirady P; Kimura T; Egawa S; Shariat SF
Urol Oncol; 2023 Apr; 41(4):177-191. PubMed ID: 35970698
[TBL] [Abstract][Full Text] [Related]
11. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial.
Kitajima K; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Sasaki R; Narita M; Yamakado K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345121
[TBL] [Abstract][Full Text] [Related]
12. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
13. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223.
Miyoshi Y; Tsutsumi S; Kawahara T; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Hayashi N; Yao M; Uemura H
BJUI Compass; 2021 Jan; 2(1):24-30. PubMed ID: 35474664
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
